CAS: 4815-28-5; 2-Amino-4,5,6,7-Tetrahydro-1-Benzothiophene-3-Carboxamide

上下游产品

2-氨基-3-腈基-4,5,6,7--四氢苯并[b]噻吩 3-Cyano-2-Amino-4,5,6,7-Tetrahydrobenzo[b]Thiophene 4651-91-6

2-氨基-3-腈基-4,5,6,7--四氢苯并[b]噻吩置于sodium Hydroxide体系中,用 乙醇,乙腈 作为反应溶剂,化学反应 4.0H,反应生成 2-氨基-4,5,6,7-四氢苯并[b]噻吩-3-甲酰胺
参考文献:Uses Of 1-(3-Cyano-4,5,6,7-Tetrahydrobenzo[B]-Thiophen-2-yl)-3-Dodecanoylthiourea As A Building Block In The Synthesis Of Fused Pyrimidine And Thiazine Systems
标题:Uses Of 1-(3-Cyano-4,5,6,7-Tetrahydrobenzo[B]-Thiophen-2-yl)-3-Dodecanoylthiourea As A Building Block In The Synthesis Of Fused Pyrimidine And Thiazine Systems
摘要:异硫氰酸月桂酰酯和 2-氨基-4,5,6,7-四氢苯并[b]噻吩-3-甲腈反应合成了标题化合物 2.化合物 2 可以作为合成许多目标杂环系统的主要结构单元.化合物 2 与乙醇钠,水合肼,苯基肼,肼基甲酸乙酯,硫脲和/或 2-氨基苯硫酚反应合成了多种融合嘧啶.微量分析和光谱数据证实了合成化合物的结构.
DOI:10.1248/cpb.C15-00047

专利信息

专利号:US-2007275962-A1
优先权日:2003-09-10
标 题:Heterobicyclic Compounds as Pharmaceutically Active Agents
发明人：KOUL ANIL; KLEBL BERT; MULLER GERHARD; MISSIO ANDREA; SCHWAB WILFRIED; HAFENBRADL DORIS; NEUMANN LARS; SOMMER MARC-NICOLA; MULLER STEFAN; HOPPE EDMUND; FREISLEBEN ACHIM; BACKES ALEXANDER; HARTUNG CHRISTIAN; FELBER BEATRICE; ZECH BIRGIT; ENGKVIST OLA; KERI GYORGY; ORFI LASZLO; BANHEGYI PETER; GREFF ZOLTAN; HORVATH ZOLTAN; VARGA ZOLTAN; MARKO PETER; PATO JANOS; SZABADKAI ISTVAN; SZEKELYHID ZSOLT; WACZEK FRIGYES
权利人:GPC BIOTECH AG
摘要:Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.